Aardvark Therapeutics (AARD) vs Genelux (GNLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Genelux (GNLX) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 47.4% versus a loss of 72.5%. Genelux is the larger company by market cap ($113.1 million vs $103.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | GNLX |
|---|---|---|
| Share price | $4.71 | $2.50 |
| Market cap | $103.08M | $113.11M |
| 1-day change | -5.04% | -0.79% |
| YTD return | -64.11% | -42.66% |
| 1-year return | -72.50% | -47.37% |
| EPS (TTM) | $-3.21 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $8.54 |
| 52-week low | $3.35 | $2.29 |
| Distance from 52-week high | -72.38% | -70.71% |
| Analyst consensus | buy | none |
| Avg. price target upside | +135.88% | +653.20% |
| Average volume | 208.11K | 276.16K |
| Shares outstanding | 21.88M | 45.25M |
| Employees | 28 | 25 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GNLX has outperformed AARD by 25.1 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Healthcare · Biotechnology · 28 employees
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Healthcare · Biotechnology · 25 employees
AARD vs GNLX FAQ
Which is bigger, Aardvark Therapeutics or Genelux?
Genelux (GNLX) is larger, with a market capitalization of $113.11M compared with $103.08M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or GNLX?
GNLX returned -47.37% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Genelux in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.